ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jun 2024
Last Updated on 04 Jun 2024
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Galcanezumab 120 mg/mL solution for injection in pre-filled pen for prophylaxis of migraine in adults who have at least four migraine days a month prior to commencement of treatment with galcanezumab. Patients must have experienced an inadequate response, intolerance, or a contraindication to at least three migraine prophylactic medications. Treatment with galcanezumab should be stopped after 12 weeks if:

    a) in episodic migraine, the number of migraine days per month does not reduce by at least 50% compared with baseline;
    b) in chronic migraine, the number of migraine days per month does not reduce by at least 30% compared with baseline.

Funding status

Galcanezumab 120 mg/mL solution for injection in pre-filled pen is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024.

MAF assistance does not apply to galcanezumab 100 mg/mL solution for injection in pre-filled syringe, or any formulations or strengths of eptinezumab, erenumab or fremanezumab.


Calcitonin gene-related peptide monoclonal antibodies for prophylaxis of migraine (Published 4 Jun 24) PES Monoclonal antibodies for preventing migraine (Published 4 Jun 24)